Abcam plc (NASDAQ: ABCM) Stock Competitors & Peer Comparison

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, VRTX has a market cap of 121.1B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while VRTX trades at $477.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas VRTX's P/E ratio is 25.35. In terms of profitability, ABCM's ROE is -0.01%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, ABCM is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check VRTX's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, REGN has a market cap of 78.6B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while REGN trades at $762.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas REGN's P/E ratio is 16.71. In terms of profitability, ABCM's ROE is -0.01%, compared to REGN's ROE of +0.18%. Regarding short-term risk, ABCM is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check REGN's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ABCM's ROE is -0.01%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, ABCM is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ABCM.Check VRNA's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, ARGX has a market cap of 54.3B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while ARGX trades at $853.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas ARGX's P/E ratio is 78.75. In terms of profitability, ABCM's ROE is -0.01%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, ABCM is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check ARGX's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ABCM's ROE is -0.01%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ABCM is less volatile compared to SGEN. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check SGEN's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, RVMDW has a market cap of 42.7B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while RVMDW trades at $9.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas RVMDW's P/E ratio is -2.32. In terms of profitability, ABCM's ROE is -0.01%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, ABCM is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check RVMDW's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, RVMD has a market cap of 39.9B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while RVMD trades at $187.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas RVMD's P/E ratio is -26.52. In terms of profitability, ABCM's ROE is -0.01%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, ABCM is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check RVMD's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, ONC has a market cap of 33.8B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while ONC trades at $316.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas ONC's P/E ratio is 70.70. In terms of profitability, ABCM's ROE is -0.01%, compared to ONC's ROE of +0.12%. Regarding short-term risk, ABCM is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check ONC's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, ALNY has a market cap of 27.4B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while ALNY trades at $205.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas ALNY's P/E ratio is 37.02. In terms of profitability, ABCM's ROE is -0.01%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, ABCM is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check ALNY's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, ROIV has a market cap of 24.5B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while ROIV trades at $33.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas ROIV's P/E ratio is -34.86. In terms of profitability, ABCM's ROE is -0.01%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, ABCM is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check ROIV's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, INCY has a market cap of 24.2B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while INCY trades at $119.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas INCY's P/E ratio is 16.06. In terms of profitability, ABCM's ROE is -0.01%, compared to INCY's ROE of +0.30%. Regarding short-term risk, ABCM is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check INCY's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while BNTX trades at $90.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas BNTX's P/E ratio is -19.61. In terms of profitability, ABCM's ROE is -0.01%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, ABCM is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check BNTX's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, UTHR has a market cap of 22B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while UTHR trades at $517.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas UTHR's P/E ratio is 19.10. In terms of profitability, ABCM's ROE is -0.01%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ABCM is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check UTHR's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, MRNA has a market cap of 21.8B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while MRNA trades at $54.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas MRNA's P/E ratio is -6.73. In terms of profitability, ABCM's ROE is -0.01%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, ABCM is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check MRNA's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, INSM has a market cap of 21.4B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while INSM trades at $98.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas INSM's P/E ratio is -17.15. In terms of profitability, ABCM's ROE is -0.01%, compared to INSM's ROE of -1.30%. Regarding short-term risk, ABCM is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check INSM's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ABCM's ROE is -0.01%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, ABCM is less volatile compared to BGNE. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check BGNE's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ABCM's ROE is -0.01%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ABCM is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check DNA-WT's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while GMAB trades at $28.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas GMAB's P/E ratio is 20.77. In terms of profitability, ABCM's ROE is -0.01%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, ABCM is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check GMAB's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, NBIX has a market cap of 16.8B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while NBIX trades at $166.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas NBIX's P/E ratio is 24.10. In terms of profitability, ABCM's ROE is -0.01%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, ABCM is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check NBIX's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while JAZZ trades at $252.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas JAZZ's P/E ratio is 19.66. In terms of profitability, ABCM's ROE is -0.01%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, ABCM is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check JAZZ's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, BBIO has a market cap of 15.7B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while BBIO trades at $80.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas BBIO's P/E ratio is -21.41. In terms of profitability, ABCM's ROE is -0.01%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, ABCM is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check BBIO's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, ASND has a market cap of 15.1B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while ASND trades at $243.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas ASND's P/E ratio is -100.79. In terms of profitability, ABCM's ROE is -0.01%, compared to ASND's ROE of -56.42%. Regarding short-term risk, ABCM is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check ASND's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, EXEL has a market cap of 13.3B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while EXEL trades at $53.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas EXEL's P/E ratio is 15.88. In terms of profitability, ABCM's ROE is -0.01%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, ABCM is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check EXEL's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ABCM's ROE is -0.01%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ABCM is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ABCM.Check KRTX's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, ARWR has a market cap of 11.9B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while ARWR trades at $84.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas ARWR's P/E ratio is -39.37. In terms of profitability, ABCM's ROE is -0.01%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, ABCM is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check ARWR's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while BMRN trades at $60.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas BMRN's P/E ratio is 28.86. In terms of profitability, ABCM's ROE is -0.01%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, ABCM is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check BMRN's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while TECH trades at $72.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas TECH's P/E ratio is 37.16. In terms of profitability, ABCM's ROE is -0.01%, compared to TECH's ROE of +0.05%. Regarding short-term risk, ABCM is less volatile compared to TECH. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check TECH's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ABCM's ROE is -0.01%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ABCM is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ABCM.Check RNAM's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, AXSM has a market cap of 11.2B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while AXSM trades at $217.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas AXSM's P/E ratio is -56.92. In terms of profitability, ABCM's ROE is -0.01%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, ABCM is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check AXSM's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, MDGL has a market cap of 10.8B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while MDGL trades at $467.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas MDGL's P/E ratio is -36.51. In terms of profitability, ABCM's ROE is -0.01%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, ABCM is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check MDGL's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, SMMT has a market cap of 10.1B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while SMMT trades at $13.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas SMMT's P/E ratio is -8.14. In terms of profitability, ABCM's ROE is -0.01%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, ABCM is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check SMMT's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while KRYS trades at $341.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas KRYS's P/E ratio is 45.60. In terms of profitability, ABCM's ROE is -0.01%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ABCM is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check KRYS's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, HALO has a market cap of 9.8B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while HALO trades at $82.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas HALO's P/E ratio is 17.87. In terms of profitability, ABCM's ROE is -0.01%, compared to HALO's ROE of +1.26%. Regarding short-term risk, ABCM is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check HALO's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while CYTK trades at $77.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas CYTK's P/E ratio is -13.23. In terms of profitability, ABCM's ROE is -0.01%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, ABCM is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check CYTK's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ABCM's ROE is -0.01%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ABCM is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ABCM.Check RXDX's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while ABVX trades at $124.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas ABVX's P/E ratio is -65.48. In terms of profitability, ABCM's ROE is -0.01%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ABCM is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check ABVX's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ABCM's ROE is -0.01%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ABCM is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ABCM.Check NUVL's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, CRNX has a market cap of 8.8B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while CRNX trades at $83.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas CRNX's P/E ratio is -16.28. In terms of profitability, ABCM's ROE is -0.01%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ABCM is less volatile compared to CRNX. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check CRNX's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while PTGX trades at $136.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas PTGX's P/E ratio is -75.49. In terms of profitability, ABCM's ROE is -0.01%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, ABCM is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check PTGX's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ABCM's ROE is -0.01%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ABCM is less volatile compared to IMGN. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check IMGN's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, IONS has a market cap of 8.6B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while IONS trades at $51.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas IONS's P/E ratio is -30.10. In terms of profitability, ABCM's ROE is -0.01%, compared to IONS's ROE of -1.11%. Regarding short-term risk, ABCM is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check IONS's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, PRAX has a market cap of 8.6B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while PRAX trades at $307.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas PRAX's P/E ratio is -23.02. In terms of profitability, ABCM's ROE is -0.01%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, ABCM is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check PRAX's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, SYRE has a market cap of 8.5B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while SYRE trades at $98.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas SYRE's P/E ratio is -47.27. In terms of profitability, ABCM's ROE is -0.01%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, ABCM is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check SYRE's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, KYMR has a market cap of 8.5B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while KYMR trades at $103.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas KYMR's P/E ratio is -29.29. In terms of profitability, ABCM's ROE is -0.01%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, ABCM is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check KYMR's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, ALKS has a market cap of 8.4B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while ALKS trades at $48.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas ALKS's P/E ratio is 52.66. In terms of profitability, ABCM's ROE is -0.01%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, ABCM is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check ALKS's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ABCM's ROE is -0.01%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ABCM is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ABCM.Check BPMC's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while APGE trades at $134.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas APGE's P/E ratio is -30.97. In terms of profitability, ABCM's ROE is -0.01%, compared to APGE's ROE of -0.33%. Regarding short-term risk, ABCM is less volatile compared to APGE. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check APGE's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas CERE's P/E ratio is -16.47. In terms of profitability, ABCM's ROE is -0.01%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ABCM is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ABCM.Check CERE's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, TGTX has a market cap of 8B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while TGTX trades at $52.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas TGTX's P/E ratio is 17.88. In terms of profitability, ABCM's ROE is -0.01%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, ABCM is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check TGTX's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, IMVT has a market cap of 7.9B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while IMVT trades at $38.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas IMVT's P/E ratio is -14.46. In terms of profitability, ABCM's ROE is -0.01%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, ABCM is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check IMVT's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, PCVX has a market cap of 7.8B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while PCVX trades at $54.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas PCVX's P/E ratio is -7.86. In terms of profitability, ABCM's ROE is -0.01%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, ABCM is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check PCVX's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while IBRX trades at $7.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas IBRX's P/E ratio is -8.44. In terms of profitability, ABCM's ROE is -0.01%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, ABCM is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check IBRX's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ABCM's ROE is -0.01%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ABCM is less volatile compared to MTSR. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check MTSR's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ABCM's ROE is -0.01%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, ABCM is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ABCM.Check MRUS's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while RYTM trades at $99.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas RYTM's P/E ratio is -31.71. In terms of profitability, ABCM's ROE is -0.01%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, ABCM is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check RYTM's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ABCM's ROE is -0.01%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ABCM is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ABCM.Check ACLX's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, COGT has a market cap of 6.7B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while COGT trades at $38.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas COGT's P/E ratio is -18.45. In terms of profitability, ABCM's ROE is -0.01%, compared to COGT's ROE of -0.83%. Regarding short-term risk, ABCM is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check COGT's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas RETA's P/E ratio is -66.29. In terms of profitability, ABCM's ROE is -0.01%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ABCM is similarly volatile compared to RETA. This indicates similar risk in terms of short-term price fluctuations for ABCM.Check RETA's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, MIRM has a market cap of 6.5B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while MIRM trades at $105.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas MIRM's P/E ratio is -7.78. In terms of profitability, ABCM's ROE is -0.01%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, ABCM is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check MIRM's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while BLTE trades at $158.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas BLTE's P/E ratio is -84.82. In terms of profitability, ABCM's ROE is -0.01%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, ABCM is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check BLTE's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, ERAS has a market cap of 6.3B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while ERAS trades at $18.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas ERAS's P/E ratio is -19.51. In terms of profitability, ABCM's ROE is -0.01%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, ABCM is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check ERAS's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while CGON trades at $71.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas CGON's P/E ratio is -30.55. In terms of profitability, ABCM's ROE is -0.01%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ABCM is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check CGON's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ABCM's ROE is -0.01%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ABCM is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ABCM.Check CNTA's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, XENE has a market cap of 6.1B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while XENE trades at $62.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas XENE's P/E ratio is -13.33. In terms of profitability, ABCM's ROE is -0.01%, compared to XENE's ROE of -0.49%. Regarding short-term risk, ABCM is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check XENE's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while LGND trades at $287.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas LGND's P/E ratio is 34.48. In terms of profitability, ABCM's ROE is -0.01%, compared to LGND's ROE of +0.16%. Regarding short-term risk, ABCM is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check LGND's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while SRRK trades at $47.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas SRRK's P/E ratio is -13.17. In terms of profitability, ABCM's ROE is -0.01%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, ABCM is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check SRRK's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, PTCT has a market cap of 5.6B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while PTCT trades at $68.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas PTCT's P/E ratio is -29.19. In terms of profitability, ABCM's ROE is -0.01%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, ABCM is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check PTCT's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ABCM's ROE is -0.01%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, ABCM is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ABCM.Check CDTX's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ABCM's ROE is -0.01%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ABCM is less volatile compared to ISEE. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check ISEE's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas APLS's P/E ratio is 38.35. In terms of profitability, ABCM's ROE is -0.01%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ABCM is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ABCM.Check APLS's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while TVTX trades at $55.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas TVTX's P/E ratio is -254.05. In terms of profitability, ABCM's ROE is -0.01%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, ABCM is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check TVTX's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas TERN's P/E ratio is -51.41. In terms of profitability, ABCM's ROE is -0.01%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ABCM is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ABCM.Check TERN's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while DFTX trades at $43.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas DFTX's P/E ratio is N/A. In terms of profitability, ABCM's ROE is -0.01%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, ABCM is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check DFTX's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, DYN has a market cap of 4.6B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while DYN trades at $25.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas DYN's P/E ratio is -7.82. In terms of profitability, ABCM's ROE is -0.01%, compared to DYN's ROE of -0.64%. Regarding short-term risk, ABCM is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check DYN's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while CRSP trades at $47.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas CRSP's P/E ratio is -9.39. In terms of profitability, ABCM's ROE is -0.01%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, ABCM is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check CRSP's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ABCM's ROE is -0.01%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ABCM is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ABCM.Check FOLD's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ABCM's ROE is -0.01%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ABCM is less volatile compared to AKRO. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check AKRO's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, DNTH has a market cap of 4.5B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while DNTH trades at $106.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas DNTH's P/E ratio is -25.89. In terms of profitability, ABCM's ROE is -0.01%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, ABCM is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check DNTH's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ABCM's ROE is -0.01%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ABCM is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ABCM.Check ALPN's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while ACAD trades at $25.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas ACAD's P/E ratio is 12.68. In terms of profitability, ABCM's ROE is -0.01%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, ABCM is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check ACAD's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while CAI trades at $15.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas CAI's P/E ratio is -86.19. In terms of profitability, ABCM's ROE is -0.01%, compared to CAI's ROE of +0.06%. Regarding short-term risk, ABCM is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check CAI's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while MANE trades at $105.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas MANE's P/E ratio is -33.36. In terms of profitability, ABCM's ROE is -0.01%, compared to MANE's ROE of -0.84%. Regarding short-term risk, ABCM is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check MANE's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas OPT's P/E ratio is -1.52. In terms of profitability, ABCM's ROE is -0.01%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ABCM is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ABCM.Check OPT's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas PRTC's P/E ratio is -3.78. In terms of profitability, ABCM's ROE is -0.01%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, ABCM is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check PRTC's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, CELC has a market cap of 4.2B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while CELC trades at $86.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas CELC's P/E ratio is -22.15. In terms of profitability, ABCM's ROE is -0.01%, compared to CELC's ROE of -2.45%. Regarding short-term risk, ABCM is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check CELC's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, EWTX has a market cap of 4.1B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while EWTX trades at $38.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas EWTX's P/E ratio is -23.15. In terms of profitability, ABCM's ROE is -0.01%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, ABCM is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check EWTX's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ABCM's ROE is -0.01%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ABCM is less volatile compared to MRTX. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check MRTX's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while ELVN trades at $54.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas ELVN's P/E ratio is -32.82. In terms of profitability, ABCM's ROE is -0.01%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, ABCM is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check ELVN's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas CPRX's P/E ratio is 12.30. In terms of profitability, ABCM's ROE is -0.01%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ABCM is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ABCM.Check CPRX's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ABCM's ROE is -0.01%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ABCM is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ABCM.Check RYZB's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ABCM's ROE is -0.01%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ABCM is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for ABCM.Check CBAY's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while VKTX trades at $31.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas VKTX's P/E ratio is -7.67. In terms of profitability, ABCM's ROE is -0.01%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, ABCM is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check VKTX's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while DNLI trades at $23.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas DNLI's P/E ratio is -7.99. In terms of profitability, ABCM's ROE is -0.01%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, ABCM is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check DNLI's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, ORKA has a market cap of 3.6B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while ORKA trades at $96.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas ORKA's P/E ratio is -49.75. In terms of profitability, ABCM's ROE is -0.01%, compared to ORKA's ROE of -0.26%. Regarding short-term risk, ABCM is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check ORKA's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while ADPT trades at $22.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas ADPT's P/E ratio is -41.80. In terms of profitability, ABCM's ROE is -0.01%, compared to ADPT's ROE of -0.31%. Regarding short-term risk, ABCM is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check ADPT's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, ALMS has a market cap of 3.6B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while ALMS trades at $28.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas ALMS's P/E ratio is -7.39. In terms of profitability, ABCM's ROE is -0.01%, compared to ALMS's ROE of -0.55%. Regarding short-term risk, ABCM is less volatile compared to ALMS. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check ALMS's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, RCUS has a market cap of 3.5B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while RCUS trades at $28.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas RCUS's P/E ratio is -8.66. In terms of profitability, ABCM's ROE is -0.01%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, ABCM is less volatile compared to RCUS. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check RCUS's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ABCM's ROE is -0.01%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, ABCM is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for ABCM.Check SWTX's competition here

Abcam plc (NASDAQ: ABCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABCM stands at 5.5B. In comparison, ARQT has a market cap of 3.5B. Regarding current trading prices, ABCM is priced at $23.99 on the NASDAQ, while ARQT trades at $26.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABCM currently has a P/E ratio of 2399.00, whereas ARQT's P/E ratio is -933.00. In terms of profitability, ABCM's ROE is -0.01%, compared to ARQT's ROE of -0.01%. Regarding short-term risk, ABCM is less volatile compared to ARQT. This indicates lower risk in terms of short-term price fluctuations for ABCM.Check ARQT's competition here